Clinical Predictors of Cetuximab for First-Line Therapy of Metastatic Colorectal Cancer: A Single Institutional Retrospective Study — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Clinical Predictors of Cetuximab for First-Line Therapy of Metastatic Colorectal Cancer: A Single Institutional Retrospective Study
Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
,
Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan
,
Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan
,
Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
,
Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
,
Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
,
Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
,
Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
,
Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
1 Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
2 Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan
3 Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan
4 Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
5 Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
6 Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
7 Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
8 Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
9 Department of Pharmacy, Okayama Rosai Hospital, Okayama, Japan
Predictive factors of cetuximab efficacy for metastatic colorectal cancer (mCRC) have not been sufficiently revealed. The present study aimed to explore new predictors. A total of 30 patients with KRAS exon 2 wild-type unresectable mCRC, who had been treated with cetuximab-based regimen as first-line therapy, were retrospectively analyzed. We assessed whether gender, age, primary tumor site, RAS genotype, the Eastern Cooperative Oncology Group Performance Status (ECOG PS), metastatic status, histological grade, carcinoembryonic antigen (CEA), treatment regimen, and oxaliplatin-based adjuvant chemotherapy at baseline were associated with cetuximab efficacy. Progression-free survival (PFS) and objective response rate (ORR) were evaluated and statistically analyzed. Analysis of PFS revealed that left-sided tumor and good PS had relevance to good results. PFS among patients with left-sided CRC was longer than that among those with right-sided CRC (median, 10.6 and 3.5 months, respectively). Patients with a PS of 0 - 1 experienced significantly longer PFS than those with a PS of 2 - 3 (median, 8.6 versus 1.3 months, respectively). In analysis of ORR, high histological grade and serum CEA level showed interaction with good effect. Patients with histological grade I/II cancer experienced better ORR than those with histological grade III/IV cancer (76% versus 20%, respectively). ORR among patients with serum CEA level higher than 5.0 ng/ml was significantly higher than that among those with lower serum levels (88% versus 38%, respectively). ECOG PS, tumor location, histological grade, and serum CEA level at baseline might be useful predictors of cetuximab efficacy in the first-line treatment of mCRC.
Goldstein, N.S. and Armin, M. (2001) Epidermal Growth Factor Receptor Immunohistochemical Reactivity in Patients with American Joint Committee on Cancer Stage Iv Colon Adenocarcinoma: Implications for a Standardized Scoring System. Cancer, 92, 1331-1346. https://doi.org/10.1002/1097-0142(20010901)92:5 3.0.CO;2-M
Mayer, A., Takimoto, M., Fritz, E., Schellander, G., Kofler, K. and Ludwig, H. (1993) The Prognostic Significance of Proliferating Cell Nuclear Antigen, Epidermal Growth Factor Receptor, and Mdr Gene Expression in Colorectal Cancer. Cancer, 71, 2454-2460. https://doi.org/10.1002/1097-0142(19930415)71:8 3.0.CO;2-2
Porebska, I., Harlozinska, A. and Bojarowski, T. (2000) Expression of the Tyrosine Kinase Activity Growth Factor Receptors (Egfr, Erb B2, Erb B3) in Colorectal Adenocarcinomas and Adenomas. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 21, 105-115. https://doi.org/10.1159/000030116
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., Chau, I. and Van Cutsem, E. (2004) Cetuximab Monotherapy and Cetuximab Plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. New England Journal of Medicine, 351, 337-345. https://doi.org/10.1056/NEJMoa033025
Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O’Callaghan, C.J., Tu, D., Tebbutt, N.C., Simes, R.J., Chalchal, H., Shapiro, J.D., Robitaille, S., Price, T.J., Shepherd, L., Au, H.J., Langer, C., Moore, M.J. and Zalcberg, J.R. (2008) K-Ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. The New England Journal of Medicine, 359, 1757-1765. https://doi.org/10.1056/NEJMoa0804385
Van Cutsem, E., Kohne, C.H., Lang, I., Folprecht, G., Nowacki, M.P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., Schlichting, M., Zubel, A., Celik, I., Rougier, P. and Ciardiello, F. (2011) Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor Kras and Braf Mutation Status. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 2011-2019. https://doi.org/10.1200/JCO.2010.33.5091
Van Cutsem, E., Lenz H.J., Kohne, C.H., Heinemann, V., Tejpar, S., Melezinek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H. and Ciardiello, F. (2015) Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and Ras Mutations in Colorectal Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33, 692-700. https://doi.org/10.1200/JCO.2014.59.4812
Lo Nigro, C., Ricci, V., Vivenza, D., Granetto, C., Fabozzi, T., Miraglio, E. and Merlano, M.C. (2016) Prognostic and Predictive Biomarkers in Metastatic Colorectal Cancer Anti-Egfr Therapy. World journal of gastroenterology, 22, 6944-6954. https://doi.org/10.3748/wjg.v22.i30.6944
Jonker, D.J., Karapetis, C.S., Harbison, C., O’Callaghan, C.J., Tu, D., Simes, R.J., Malone, D.P., Langer, C., Tebbutt, N., Price, T.J., Shapiro, J., Siu, L.L., Wong, R.P., Bjarnason, G., Moore, M.J., Zalcberg, J.R. and Khambata-Ford, S. (2014) Epiregulin Gene Expression as a Biomarker of Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer. British Journal of Cancer, 110, 648-655. https://doi.org/10.1038/bjc.2013.753
Brule, S.Y., Jonker, D.J., Karapetis, C.S., O’Callaghan, C.J., Moore, M.J., Wong, R., Tebbutt, N.C., Underhill, C., Yip, D., Zalcberg, J.R., Tu, D. and Goodwin, R.A. (2015) Location of Colon Cancer (Right-Sided Versus Left-Sided) as a Prognostic Factor and a Predictor of Benefit from Cetuximab in Ncic Co.17. European Journal of Cancer (Oxford, England: 1990), 51, 1405-1414. https://doi.org/10.1016/j.ejca.2015.03.015
Von Einem, J.C., Heinemann, V., von Weikersthal, L.F., Vehling-Kaiser, U., Stauch, M., Hass, H.G., Decker, T., Klein, S., Held, S., Jung, A., Kirchner, T., Haas, M., Holch, J., Michl, M., Aubele, P., Boeck, S., Schulz, C., Giessen, C., Stintzing, S. and Modest, D.P. (2014) Left-Sided Primary Tumors Are Associated with Favorable Prognosis in Patients with Kras Codon 12/13 Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab Plus Chemotherapy: An Analysis of the Aio Krk-0104 Trial. Journal of Cancer Research and Clinical Oncology, 140, 1607-1614. https://doi.org/10.1007/s00432-014-1678-3
Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweij, J. (2009) New Response Evaluation Criteria in Solid Tumours: Revised Recist Guideline (Version 1.1). European Journal of Cancer (Oxford, England: 1990), 45, 228-247.
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T. and Carbone, P.P. (1982) Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649-655. https://doi.org/10.1097/00000421-198212000-00014
Barresi, V., Reggiani Bonetti, L., Ieni, A., Caruso, R.A. and Tuccari, G. (2015) Histological Grading in Colorectal Cancer: New Insights and Perspectives. Histology and Histopathology, 30, 1059-1067.
Kanda, Y. (2013) Investigation of the Freely Available Easy-to-Use Software “Ezr” for Medical Statistics. Bone Marrow Transplantation, 48, 452-458. https://doi.org/10.1038/bmt.2012.244
Jonker, D.J., O’Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.J., Berry, S.R., Krahn, M., Price, T., Simes, R.J., Tebbutt, N.C., van Hazel, G., Wierzbicki, R., Langer, C. and Moore, M.J. (2007) Cetuximab for the Treatment of Colorectal Cancer. The New England Journal of Medicine, 357, 2040-2048. https://doi.org/10.1056/NEJMoa071834
Venook, A.P., Niedzwiecki, D., Innocenti, F, et al. (2016) Impact of Primary (1o) Tumor Location on Overall Survival (Os) and Progression-Free Survival (Pfs) in Patients (Pts) with Metastatic Colorectal Cancer (Mcrc): Analysis of Calgb/Swog 80405 (Alliance). Journal of Clinical Oncology, 34, 3504-3504.
McKay, J.A., Murray, L.J., Curran, S., Ross, V.G., Clark, C., Murray, G.I., Cassidy, J. and McLeod, H.L. (2002) Evaluation of the Epidermal Growth Factor Receptor (Egfr) in Colorectal Tumours and Lymph Node Metastases. European Journal of Cancer (Oxford, England: 1990), 38, 2258-2264.
Steele, R.J., Kelly, P., Ellul, B. and Eremin, O. (1990) Immunohistochemical Detection of Epidermal Growth Factor Receptors on Human Colonic Carcinomas. British Journal of Cancer, 61, 325-326. https://doi.org/10.1038/bjc.1990.63
Steele, R.J., Kelly, P., Ellul, B. and Eremin, O. (1990) Epidermal Growth Factor Receptor Expression in Colorectal Cancer. The British Journal of Surgery, 77, 1352-1354. https://doi.org/10.1002/bjs.1800771211
Goldstein, M.J. and Mitchell, E.P. (2005) Carcinoembryonic Antigen in the Staging and Follow-Up of Patients with Colorectal Cancer. Cancer Investigation, 23, 338-351. https://doi.org/10.1081/CNV-58878
Locker, G.Y., Hamilton, S., Harris, J., Jessup, J.M., Kemeny, N., Macdonald, J.S., Somerfield, M.R., Hayes, D.F. and Bast, R.C. (2006) Asco 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 24, 5313-5327. https://doi.org/10.1200/JCO.2006.08.2644
Bhatnagar, J., Tewari, H.B., Bhatnagar, M. and Austin, G.E. (1999) Comparison of Carcinoembryonic Antigen in Tissue and Serum with Grade and Stage of Colon Cancer. Anticancer Research, 19, 2181-2187.
Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D.B., Jonker, D., Osborne, S., Andre, N., Waterkamp, D. and Saunders, M.P. (2013) Bevacizumab plus Capecitabine versus Capecitabine Alone in Elderly Patients with Previously Untreated Metastatic Colorectal Cancer (Avex): An Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 14, 1077-1085.